News
Novo Nordisk Inc. has won an adverse jury instruction sanction against Washington state for its failure to preserve evidence in a False Claims Act case against the pharmaceutical company.
Novo Nordisk Mexico and the Salvador Zubirán Institute signed a major agreement to develop clinical studies in ...
Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...
Hosted on MSN1mon
Why Novo Nordisk Stock Popped on TuesdayNovo Nordisk (NYSE: NVO) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight loss market. As Reuters reports today, an online weight loss company ...
Mads Claus Rasmussen / Ritzau Scanpix / AFP / Getty Images U.S.-listed shares of Novo Nordisk (NVO) declined in the opening minutes of trading Friday on the surprise news that CEO Lars Fruergaard ...
May 16 (UPI) --Novo Nordisk announced Friday that CEO Lars Fruergaard Jorgensen is stepping down per mutual agreement with the company. The company said Friday that Jorgensen will continue as CEO ...
Novo Nordisk CEO Lars Fruergaard Jørgensen to step down amid board and market pressure. Despite leadership changes, the company maintains its strategy. Last Chance: See the "Power Pattern" That ...
Novo Nordisk announced Friday that it would part ways with its longtime CEO, who steered the company into an unprecedented boom time for weight-loss drugs. The Ozempic maker’s chief executive ...
Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen is stepping down after eight years in the role, during which he led the company to an all-time high in the markets. Despite being the first to ...
Despite Novo Nordisk's stock decline, the company's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases. Eli Lilly's oral weight-loss drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results